System and method for diagnosis and treatment
AssigneePop Test Oncology Limited Liability Company
InventorsRandice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
Life of this patent
Estimating the term…
Abstract
This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.
Claims10
A pharmaceutical composition for treating neoplasia in a patient which is characterized by expression of a glucocorticoid receptor, comprising:
- a) therapeutically effective amounts of at least one neoplasia-treating agent selected from the group consisting of taxanes, and combinations thereof;
- b) the GCR (glucocorticoid receptor) antagonist ORG 34517;
- and
- c) optionally, at least one pharmaceutically acceptable carrier;
- wherein the neoplasia is selected from the group consisting of hepatocellular carcinoma, breast cancer, prostate cancer, lung cancer, and ovarian cancer.
A pharmaceutical composition for treating neoplasia in a patient which is characterized by expression of a glucocorticoid receptor, comprising:
- a) therapeutically effective amounts of at least one neoplasia-treating agent selected from the group consisting of abiraterone, pharmaceutically acceptable salts thereof, derivatives thereof, and combinations thereof;
- b) the GCR (glucocorticoid receptor) antagonist ORG 34517;
- and
- c) optionally, at least one pharmaceutically acceptable carrier;
- wherein the neoplasia is selected from the group consisting of hepatocellular carcinoma, breast cancer, prostate cancer, lung cancer, and ovarian cancer.
Dependencies are inferred from the claim text.